Patent ID: 8349332
Filing Date: 2013-01-08
Classification: A61K,A61P,C07K

Abstract:
1. A method of killing CD20 + and/or CD22 + cells, comprising exposing the cells to a hexavalent DNL complex comprising: a. a first fusion protein comprising an AD moiety from the N-terminus of an AKAP protein consisting of SEQ ID NO: 16 attached to the C-terminal end of an IgG antibody, and b. four copies of a second fusion protein comprising a DDD sequence from human protein kinase A (PKA) RIα, RIβ, RIIα or RIIβ consisting of SEQ ID NO: 14 attached to the C-terminal end of a Fab antibody; wherein pairs of the DDD sequence form dimers that bind to the AD moiety to form the DNL complex; and wherein the IgG antibody and the Fab antibody fragment bind to one or more antigens selected from the group consisting of CD20 and CD22.